Fulgent Genetics (FLGT) Osake Kurssi
Fulgent Genetics Kurssi
Viimeisten 11 vuoden aikana Fulgent Geneticsn liikevaihto kasvoi 65,3 % vuodessa ja ylsi 322,67 M USD:een. Osakekohtainen tulos on kasvanut 532,4 % vuodessa viimeisten 3 vuoden aikana. Fulgent Geneticsn nettomarginaali −18,8 % on laskenut verrattuna 10,5 %:iin muutama vuosi sitten. Fulgent Geneticsn 12 kuukauden konsensustavoitehinta on 19,00 USD, noin ali kurssia 10,5 %. 6 analyytikosta 0 suosittaa ostoa — kokonaiskonsensus on Myy.
Fulgent Genetics osakekurssi
Fulgent Genetics liiketoimintamalli ja osakeanalyysi
Usein kysytyt kysymykset Fulgent Genetics -osakkeesta
The business model of Fulgent Genetics Inc focuses on providing comprehensive genetic testing solutions. The company leverages its proprietary technology platform to offer a wide range of genetic tests, empowering healthcare professionals and patients with accurate and actionable information regarding inherited diseases, cancer predisposition, and other genetic conditions. Fulgent Genetics Inc's business model revolves around offering high-quality testing services and genetic analysis for individuals, healthcare providers, researchers, and pharmaceutical companies. By combining advanced technology and expertise in genetics, Fulgent Genetics Inc aims to support personalized medicine and improve patient outcomes through precise diagnostics and genetic insight.
Fulgent Genetics Inc is primarily active in the healthcare and biotechnology industries.
The main competitors of Fulgent Genetics Inc in the market include companies like Invitae Corporation, Myriad Genetics Inc, and Genomic Health Inc.
Fulgent Genetics Inc is a leading genetic testing company headquartered in California, United States. Established in 2011, Fulgent Genetics has rapidly emerged as a trusted provider of comprehensive genetic testing solutions. The company specializes in Next Generation Sequencing (NGS) and offers a wide range of genetic tests for various applications, including cancer screening, carrier screening, and hereditary diseases. Fulgent Genetics is committed to leveraging advanced technology and bioinformatics to deliver accurate and actionable results. With its innovative approach and dedication to quality, Fulgent Genetics has become a recognized name in the field of genetic testing, serving healthcare professionals, researchers, and individuals worldwide.
Fulgent Genetics Inc has achieved several significant milestones. The company successfully developed a proprietary technology platform, called Next Generation Sequencing (NGS), which has revolutionized genetic testing. Fulgent Genetics Inc has also formed strategic partnerships with leading healthcare providers and institutions, expanding its reach and impact within the industry. The company has received numerous accreditations and certifications, highlighting its commitment to ensuring the highest quality standards in genetic testing services. Additionally, Fulgent Genetics Inc has experienced remarkable financial growth, with increasing revenue and consistent profitability, making it a leading player in the field of genetic testing.
Fulgent Genetics Inc is primarily present in several countries and regions worldwide. The company has a significant presence in the United States, where it is headquartered and operates its main operations. Fulgent Genetics Inc also extends its presence to international markets, including countries in Europe, such as Germany, France, and the United Kingdom. Additionally, the company has expanded its reach in Asia, with a presence in countries like China and Japan. Fulgent Genetics Inc's global presence allows it to serve a diverse customer base and tap into various market opportunities.
Fulgent Genetics Inc represents values of innovation, integrity, and excellence in the field of genetic testing and diagnostics. The company is committed to providing accurate and reliable results to healthcare providers and patients, helping to improve patient outcomes and personalized medicine. Fulgent Genetics' corporate philosophy revolves around staying at the forefront of genetic technology advancements, continuously expanding its test menu, and maintaining a strong focus on customer satisfaction. With its state-of-the-art laboratories and a team of highly trained professionals, Fulgent Genetics Inc remains dedicated to delivering high-quality genetic testing solutions.
Analyytikot asettavat tällä hetkellä Fulgent Genetics-osakkeelle keskimääräisen tavoitehinnan 19,00 USD (mediaani: 19,00 USD), mikä merkitsee −10,5 % viimeisimpään hintaan verrattuna. Konsensus perustuu 6 analyytikkoarvioon.
6 analyytikkoa arvioi tällä hetkellä Fulgent Genetics-osaketta: 0 suosittaa ostoa, 3 pitoa ja 3 myyntiä. Vuodelle 2026 analyytikot odottavat Fulgent Genetics-yhtiöltä 331,70 M USD liikevaihtoa ja −2,28 USD osakekohtaista tulosta.
Nykyisellä valuuttakurssilla Fulgent Genetics-osake noteerataan hintaan 18,94 EUR (21,23 USD).
Fulgent Genetics-osake (FLGT) on listattuna 4 pörssissä, muun muassa: NASDAQ (FLGT), Frankfurt (7F0.F), München (7F0.MU), Düsseldorf (7F0.DU).
The company Fulgent Genetics Inc is a leading provider of genetic testing services and solutions. Founded in 2011, the company specializes in the development and commercialization of advanced genetic tests and procedures to improve diagnostic and research applications in medicine, life sciences, and agriculture. Fulgent Genetics' business model is based on developing innovative genetic tests and procedures based on the latest scientific knowledge and technologies. The company offers a wide range of genetic tests and procedures that allow for accurate diagnosis of genetic diseases. Their products include prenatal genetic tests for early detection of congenital anomalies, cancer genetics tests for identifying cancer-causing gene mutations, tests for rare genetic diseases, carrier tests for detecting carriers of genetic diseases, and pharmacogenomics tests for personalized medicine. Fulgent Genetics operates two business segments: diagnostics and research. Under the diagnostics segment, the company provides genetic tests for clinical diagnosis of genetic diseases in medicine. These tests are used by patients, physicians, and healthcare organizations to identify genetic risks, diagnose diseases, and determine treatment options. Under the research segment, the company offers products for research institutions and companies working on researching genetic connections for the development of new treatment methods. The company has developed a user-friendly online portal that allows customers to easily access its services. The portal provides an intuitive interface for ordering genetic tests and monitoring the progress of test results. Fulgent Genetics also offers customization services for specific tests to meet the different needs of customers. Fulgent Genetics aims to become a preferred partner for healthcare organizations, research institutions, and companies for genetic diagnostic and research services. The company strives to continually improve its research and development capabilities and explore growth opportunities through expansion strategies and new partnerships. In summary, Fulgent Genetics offers a wide range of innovative and user-friendly genetic tests and procedures that enable accurate diagnosis of genetic diseases. The company aims to become a preferred partner for healthcare organizations, research institutions, and companies for genetic diagnostic and research services by continually improving its research and development capabilities and exploring growth opportunities through expansion strategies and new partnerships.
odotettu liikevaihto Fulgent Genetics on 331,70 M USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.
odotettu voitto Fulgent Genetics on −70,17 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.
Fulgent Genetics:n hinta-voitto-suhde (P/E) on tällä hetkellä −9,31. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Fulgent Genetics-osakkeen arvostusta.
Fulgent Genetics:n hinta-myynti-suhde (P/S) on tällä hetkellä 1,97. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Fulgent Genetics-osakkeen arvostuskennuslukuna.
Fulgent Genetics:n Eulpool-laatuscore on 2/10.
Fulgent Genetics:n ISIN on US3596641098. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.
Fulgent Genetics:n WKN on A2AS4N. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.
Fulgent Genetics:n ticker on FLGT. Tämä pörssinoteeraus käytetään Fulgent Genetics-osakkeiden kauppaan pörssissä.
Fulgent Genetics osake
Fulgent Genetics vertaisryhmä
Fulgent Genetics Ticker
Fulgent Genetics FIGI
Kaikki tunnusluvut ja syvällinen analyysi Fulgent Genetics:sta
Meidän osakeanalyysimme Fulgent Genetics-osakkeesta sisältää tärkeitä taloudellisia tunnuslukuja, kuten liikevaihdon, voiton, P/E-luvun, P/S-luvun, EBIT:n sekä tietoja osingosta. Lisäksi tarkastelemme asioita kuten osakkeet, markkina-arvo, velat, oma pääoma ja vastuut Fulgent Genetics:n yhteydessä. Jos etsit yksityiskohtaisempaa tietoa näistä aiheista, tarjoamme alisivuillamme kattavia analyysejä: